News

Video

Changing the Paradigms of How We Think About Depression

Check out this review of the 2023 APA Annual Meeting presentation on the efficacy and safety of repeat treatment courses using novel medicine, zuranolone.

CONFERENCE REPORTER

Greg Mattingly, MD, shares a review of the 2023 APA Annual Meeting presentation that covered long term results of the year long study on zuranolone in major depressive disorder.

Dr Mattingly is an associate clinical professor at Washington University School of Medicine, and is a physician and principal investigator in clinical trials for Midwest Research Group.

Related Videos
40 years
Have A Nice Day Photo/AdobeStock
Tasphong/AdobeStock
Andrey/AdobeStock
tardive dyskinesia
tardive dyskinesia
tardive dyskinesia
meds pills
covid
ADHD
© 2025 MJH Life Sciences

All rights reserved.